Ranbaxy in a soup again
Thursday, July 9th, 2009 | 8 viewsRanbaxy Laboratories, who has been facing problems with the US drug regulator, suffered a further blow, with Canadian generic or off-patent drug maker Apotex questioning in court the company`s ability to launch two generic drugs on schedule, reports Mint. In two separate filings in the US district court of North Carolina, Apotex has pointed to Ranbaxy`s troubles with the US food and drug administration (FDA) and said that these may prevent the Indian firm from launching two big products—generics versions of herpes drug Valtrex and Alzheimer`s drug Aricept—and thereby hurt the business of other generic companies, including the Canadian firm`s. Reason being the firms that get first permission to launch generic versions of drugs also get a so called marketing exclusivity period during which no other generic company will be allowed to launch its version
